AG Mednet renews partnership to support Median's China-based infrastructure

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/donfiore)
(Image: Getty/donfiore)

Related tags: AG Mednet, Imaging, CRO, Oncology, China

AG Mednet provides imaging services to Median Technologies in support of the company's portfolio of clinical trials, including "large programs" in China.

AG Mednet ​provides technology solutions for clinical trial adjudication and imaging to global contract research organizations (CROs).

Under its renewed partnership with Median – which provides medical image analysis and management services for global oncology trials – AG Mednet will support Median’s portfolio of trials, including its “large programs” in China, according to the company.

Median will use AG Mednet's electronic transfer solutions to manage images and enable the extraction of imaging biomarkers.

Abraham Gutman, president and CEO of AG Mednet, said China represents a significant percentage of AG Mednet users for two reasons: "Global trials are finding significant numbers of subjects there to test biologics, drugs and devices.

"Additionally, there is a clear push on the part of China to become competitive in pharma, both in the development of new therapies as well as testing more traditional Chinese medicine applications. China continues to produce highly skilled scientists and doctors."

Gutman told us, "Median has recognized that a presence in-country, staffed by local talent, allows it to service the market in more efficient and productive way. It is for this reason that AG Mednet has become their tool of choice, since we have the most robust ability to collect images globally, including in China, and deliver them to China in a continuous and reliable manner."

Related news

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars